JP6860148B2 - 治療法の有利性を予見する予見方法 - Google Patents
治療法の有利性を予見する予見方法 Download PDFInfo
- Publication number
- JP6860148B2 JP6860148B2 JP2017541433A JP2017541433A JP6860148B2 JP 6860148 B2 JP6860148 B2 JP 6860148B2 JP 2017541433 A JP2017541433 A JP 2017541433A JP 2017541433 A JP2017541433 A JP 2017541433A JP 6860148 B2 JP6860148 B2 JP 6860148B2
- Authority
- JP
- Japan
- Prior art keywords
- therapy
- folfiri
- region
- copy number
- amplification
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Medical Informatics (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Bioinformatics & Computational Biology (AREA)
- Evolutionary Biology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Theoretical Computer Science (AREA)
- Data Mining & Analysis (AREA)
- Databases & Information Systems (AREA)
- Epidemiology (AREA)
- Primary Health Care (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Description
被験者由来の大腸癌の腫瘍組織検体のヒト染色体上の特定領域を正常細胞の場合と比較してコピー数の増加の有無を測定する工程と、
前記コピー数の増加の有無に基づいて前記被験者への前記FOLFOX療法またはFOLFIRI療法の有利性を予見する工程を含み、
前記予見する工程は、
前記ヒト染色体上の特定領域が、
7q34、8q24.1、8q24.2、8q24.1−q24.2、13q12.2、のうち、少なくとも1領域であり、
前記特定領域のコピー数が増加している場合にFOLFIRI療法が有利と予見し、
前記ヒト染色体上の特定領域が、9q34.3領域であり、
前記特定領域のコピー数が増加していない場合にFOLFIRI療法が有利と予見し、
前記ヒト染色体上の特定領域が7p15.3と8q24.1であり、
前記7q15.3でコピー数の増加が認められ、前記8q24.1ではコピー数の増加が認められない場合にFOLFOX療法が有利であると予見することを特徴とする。
以下の実施例に関して用いた対象症例は、切除不能・再発結腸/直腸がん初回化学療法例に該当し、2008年9月から2012年12月までに西日本がん研究機構(West Japan Oncology Group)の「切除不能・再発結腸/直腸がん初回化学療法例に対する5−fluorouracil(5−FU)/levofolinate calcium(I−LV)+oxaliplatin(L−OHP)+bevacizumab(BEV)併用療法 対 5FU/I−LI+irinotecan(CPT−11)+BEV併用療法のランダム化比較第III相試験(WJOG4407G)」に登録され、かつWJOG4407GTRに同意が得られた患者のデータである。
まず、FFPEスライド検体からDNA抽出を行った。全部で154サンプルのDNA抽出を行った。
以後図9から図12も同様である。
次に実施例1でWJOG4407GRTに同意を得られた患者の観察期間70か月までをまとめた結果を示す。実施例1の場合より観察期間が長いので、より確度の高い結果が得られた。
Claims (1)
- 大腸癌に対してFOLFOX療法またはFOLFIRI療法の有利性を予見する予見方法であって、
被験者由来の大腸癌の腫瘍組織検体のヒト染色体上の特定領域を正常細胞の場合と比較してコピー数の増加の有無を測定する工程と、
前記コピー数の増加の有無に基づいて前記被験者への前記FOLFOX療法またはFOLFIRI療法の有利性を予見する工程を含み、
前記予見する工程は、
前記ヒト染色体上の特定領域が、
7q34、8q24.1、8q24.2、8q24.1−q24.2、13q12.2、のうち、少なくとも1領域であり、
前記特定領域のコピー数が増加している場合にFOLFIRI療法が有利と予見し、
前記ヒト染色体上の特定領域が、9q34.3領域であり、
前記特定領域のコピー数が増加していない場合にFOLFIRI療法が有利と予見し、
前記ヒト染色体上の特定領域が7p15.3と8q24.1であり、
前記7q15.3でコピー数の増加が認められ、前記8q24.1ではコピー数の増加が認められない場合にFOLFOX療法が有利であると予見する
ことを特徴とする予見方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015187300 | 2015-09-24 | ||
JP2015187300 | 2015-09-24 | ||
PCT/JP2016/004327 WO2017051542A1 (ja) | 2015-09-24 | 2016-09-23 | 治療法の選択方法およびそれを示すバイオマーカー |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2017051542A1 JPWO2017051542A1 (ja) | 2018-07-05 |
JP6860148B2 true JP6860148B2 (ja) | 2021-04-14 |
Family
ID=58385922
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017541433A Active JP6860148B2 (ja) | 2015-09-24 | 2016-09-23 | 治療法の有利性を予見する予見方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US11879150B2 (ja) |
EP (1) | EP3354744B1 (ja) |
JP (1) | JP6860148B2 (ja) |
CN (1) | CN108026589B (ja) |
WO (1) | WO2017051542A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113684277B (zh) * | 2021-09-06 | 2022-05-17 | 南方医科大学南方医院 | 一种基于基因组拷贝数变异的生物标志物预测卵巢癌同源重组缺陷的方法及应用 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000024940A1 (en) | 1998-10-28 | 2000-05-04 | Vysis, Inc. | Cellular arrays and methods of detecting and using genetic disorder markers |
CA2584723A1 (en) * | 2004-10-22 | 2006-05-04 | Redpath Integrated Pathology, Inc. | Enhanced amplifiability of minute fixative-treated tissue samples, minute stained cytology samples, and other minute sources of dna |
DE602005023646D1 (de) | 2004-12-10 | 2010-10-28 | Siemens Healthcare Diagnostics | Für die vorhersage des ansprechens maligner neoplasie auf eine auf taxan beruhende medizinische behandlung geeignete genetische veränderung |
JP2008048689A (ja) * | 2006-08-25 | 2008-03-06 | Aichi Prefecture | 生物体のタイプを判別するためのマーカーの選択方法及び選択されたマーカーの利用 |
EP2300822A1 (en) * | 2008-06-11 | 2011-03-30 | Nils Aage Brünner | Selection of colorectal cancer patients for neo-adjuvant and adjuvant systemic anti-cancer treatment |
US20110262464A1 (en) | 2008-10-03 | 2011-10-27 | Danafarber Cancer Institute, Inc. | Compositions, Kits, and Methods for the Diagnosis, Prognosis, and Monitoring of Cancer Using GOLPH3 |
ES2354922B1 (es) * | 2009-09-02 | 2012-02-07 | Fundacion Institut De Recerca De L'hospital Universitari Vall D'hebron | Marcadores para la selección de terapias personalizadas para el tratamiento del c�?ncer. |
CN104232762B (zh) * | 2009-10-26 | 2016-11-23 | 雅培分子公司 | 用于测定非小细胞肺癌预后的诊断方法 |
JP5706612B2 (ja) | 2009-12-28 | 2015-04-22 | 学校法人 埼玉医科大学 | 加齢黄斑変性症易罹患性の判定マーカー並びに判定方法及び判定キット |
CN103710451B (zh) * | 2013-12-26 | 2015-06-24 | 上海锐赛生物技术有限公司 | Pik3c2g在结直肠癌化疗疗效判断和检测试剂盒中的应用 |
EP3198035B1 (en) * | 2014-09-26 | 2022-11-02 | Allarity Therapeutics Europe ApS | Methods for predicting drug responsiveness |
CN104878083B (zh) * | 2015-03-04 | 2018-05-22 | 上海市杨浦区中心医院 | 检测folfox化疗药物对于结直肠癌有效性的试剂盒 |
CN104762375B (zh) * | 2015-03-13 | 2018-07-06 | 中山大学肿瘤防治中心 | Pou5f1b在肿瘤诊断、治疗、预后和预测复发中的应用 |
-
2016
- 2016-09-23 US US15/762,834 patent/US11879150B2/en active Active
- 2016-09-23 JP JP2017541433A patent/JP6860148B2/ja active Active
- 2016-09-23 WO PCT/JP2016/004327 patent/WO2017051542A1/ja active Application Filing
- 2016-09-23 CN CN201680055580.1A patent/CN108026589B/zh active Active
- 2016-09-23 EP EP16848333.7A patent/EP3354744B1/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP3354744A4 (en) | 2019-04-17 |
US20180285521A1 (en) | 2018-10-04 |
WO2017051542A1 (ja) | 2017-03-30 |
CN108026589B (zh) | 2022-09-06 |
CN108026589A (zh) | 2018-05-11 |
JPWO2017051542A1 (ja) | 2018-07-05 |
US11879150B2 (en) | 2024-01-23 |
EP3354744B1 (en) | 2021-09-08 |
EP3354744A1 (en) | 2018-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101437718B1 (ko) | 위암의 예후 예측용 마커 및 이를 이용하는 위암의 예후 예측 방법 | |
Vanni et al. | The current state of molecular testing in the BRAF-mutated melanoma landscape | |
JP7186700B2 (ja) | 腫瘍抑制foxo活性を酸化ストレスから区別する方法 | |
Crowley et al. | Liquid biopsy: monitoring cancer-genetics in the blood | |
US11279979B2 (en) | Method of determining PIK3CA mutational status in a sample | |
US20190049452A1 (en) | Topographic genotyping for determining the diagnosis, malignant potential, and biologic behavior of pancreatic cysts and related conditions | |
Shin et al. | Addressing the challenges of applying precision oncology | |
JP6704861B2 (ja) | 癌処置のための個別化三剤治療を選択するための方法 | |
JP6106257B2 (ja) | 非小細胞肺癌の予後を決定するための診断方法 | |
Li et al. | EGFR nuclear import in gallbladder carcinoma: nuclear phosphorylated EGFR upregulates iNOS expression and confers independent prognostic impact | |
Liu et al. | Protocadherin γ-A7 is down-regulated in colorectal cancer and associated with the prognosis in patients with wild-type KRAS | |
Berardi et al. | Impact of VEGF, VEGFR, PDGFR, HIF and ERCC1 gene polymorphisms on thymic malignancies outcome after thymectomy | |
CN110004229A (zh) | 多基因作为egfr单克隆抗体类药物耐药标志物的应用 | |
CN112119156A (zh) | 个体化检测癌症复发或转移和/或评估治疗反应的方法 | |
EP4189119A1 (en) | Biomarkers for diagnosing and monitoring lung cancer | |
JP6860148B2 (ja) | 治療法の有利性を予見する予見方法 | |
Torresan et al. | Liquid biopsy in colorectal cancer: onward and upward | |
JP7210030B2 (ja) | 早期膵がんを診断するための方法およびキット | |
Zhao et al. | Osteopontin promoter polymorphisms at locus-443 are associated with metastasis and poor prognosis of human intrahepatic cholangiocarcinoma in Chinese population | |
JP2014501496A (ja) | 消化管間質腫瘍における臨床転帰のシグネチャーおよび消化管間質腫瘍の治療の方法 | |
EP2716767A1 (en) | Method for determining the prognosis of pancreatic cancer | |
KR20100034557A (ko) | 폐선암 수술 후 초기 재발 예측용 바이오마커 | |
WO2013045464A1 (en) | Cdna biomarkers in whole blood for colorectal cancer assessment | |
US20220298565A1 (en) | Method Of Determining PIK3CA Mutational Status In A Sample | |
Kashyap et al. | A Genetic Roadmap of Gallbladder Cancer Disparities: A Potential for Development of Targeted Therapies: Gallbladder cancer: from genetics to targeted therapies. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190522 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200602 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200803 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200918 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210302 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210317 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6860148 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |